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1. Introduction
Skin cancer represents one-third of all cancers that are diagnosed every year worldwide. From
all types of skin cancer, cutaneous melanoma is the least frequent among this group of
malignant tumors, it is however, the most highly invasive and metastatic tumor. It has also
shown an important growth of around 150% in its appearance since 1971, having an estimation
of 76,250 new cases diagnosed in the USA in 2012. In 1971 there was only 1 case in 600 white
people. In the period of 1992 to 2004, its annual growth was of 3.1%. This led to an estimated
incidence of 1 in every 90 white people by 2000. By 2010 it was 1 in every 50, for people above
50 years old in the USA. Its epidemiological importance lies in its high mortality rate, since it
is the cause of 90% of deaths for skin cancer and it is potentially the most dangerous form of
skin tumor [1]. The outlook for patients with advanced melanoma is often fatal due to a lack
of effective treatments.
In Mexico, melanoma incidence is around 1.7 per 100 000 people, and the Histopathologic
Record of Malignancies in 2001 reported that it is the second most frequent. Women are the
gender most affected by Melanoma (1.6/1). The median age of presentation in this country is
54 years and in 77% of the cases there is no relation to sun exposure. On the other hand, it is
important to point out that there is a lack of formal registration of neoplasias in health
institutions of our nation [1, 2, 3].
There are four clinicopathological subtypes that Melanoma presents, which usually are
correlated to ethnic differences and to exposition to UV radiation: Superficial spreading
melanoma (SSM), Lentigo maligna melanoma (LMM), Nodular melanoma (NM) and Acral
lentiginous melanoma (ALM) [1, 4]. SSM and LMM, are the most common among Caucasians
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and their presence has been directly related to sun exposure. Nodular melanoma is less
frequent (10%) than SSM (70%), but both melanomas share pigmentary characteristics in
patients. It is probable, however, that these two types of melanoma have a direct relation with
sun exposure. However, this risk factor has not been proven in NM, given that this type can
be found in any place on the body, not just in skin areas frequently exposed to sun light.
The most frequent subtypes of Melanoma in our population are, NM and ALM [4, 5] (Figure
1). Studies supporting the hypothesis that ALM may be a biological and genetically different
subtype, will be mentioned in the following sections. Its distinct development pattern suggests
that it may possess molecular and cellular uniqueness.
This may be because of different genetic alterations that control the transformation of mela‐
nocytes to acral melanoma, leading to the need for a specific-therapeutic target towards this
subtype of melanoma with a high rate among Mexicans and Latin-Americans.
Figure 1. An indolent ALM subtype on the foot of a 58-year-old male patient, with 8 months of evolution. Nodular
melanoma (NM) and Acral Lentiginous Melanoma (ALM) are the most frequent subtypes of Melanoma in our popula‐
tion. The lower extremities (mainly on the feet) are the most common anatomic locations reported for ALM.
2. Risk factors
Several studies have identified certain variables associated with an increased risk of develop‐
ing melanoma: European ancestry, phenotype, UV radiation exposure, personal or family
history of malignant melanoma, and molecular alterations are some of the most relevant [6].
Genetic alterations, will receive particularly emphasis later in this review. It is important to
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mention, that the risk factors traditionally associated with melanoma are related principally
to Caucasians, where most clinical and basic studies are carried out. However, there are not
enough studies supporting the predisposition of such factors for the subtypes of melanoma
occuring in Mexican or Latin-American population.
Yamaguchi et  al,  reported that the risk factors traditionally described such as UV expo‐
sure,  have  a  small  influence  in  the  pathogenesis  of  dark  skin  population.  It  has  been
postulated that UV radiation plays a smaller role in the pathogenesis of melanoma in the
darker-skinned population. This is due to the fact that with an increase in melanin content,
the larger melanosomes (in darker skin), absorb and scatter more energy than the smaller
ones in lighter skin [7].
3. Sun exposure
Although various phenotypic characteristics enhance or reduce the risk of developing
melanoma, sun exposure has been reported as the main cause of SSM, LMM and NM subtypes.
The incidence of this disease is much higher in people who tend to burn rather than tan. (8)
UVA rays constitute 90% of solar radiation. However, UVB rays are greater risks for those who
traditionally work or have recreational and daily activities outside. Among those with SSM
and LMM, 75% of the affected individuals are sunburned by UVB rays. However, ALM has
not been related to this risk factor. In addition, it is known that excessive sun exposure at early
ages (childhood and adolescence) has a negative outcome in DNA reparation. The most
important exogenous factor for melanoma is UV radiation exposure, particularly intermittent
exposition, and it is known as the only etiological agent that can be modified. The increase in
sun exposure and the damage to higher levels of the atmosphere because of contamination has
resulted in an increase of the amount of radiation [9,10,11].
Sun exposure increases the expression of α-melanocyte stimulating hormone (α-MSH) and of
the peptides of pro-opiomelanocortin in the skin. Melanocyte- stimulating hormone belongs
to a group called the melanocortins. α-MSH is the most important melanocortin for pigmen‐
tation and shows a high affinity for melanocyte stimulating hormone receptor (MSHR). Once
α-MSH binds to MSHR, cellular cAMP is activated, as well as other signal transduction
pathways. The final result is the production of eumelanin.
Eumelanin, the primary pigment that colors the skin, hair and eyes in humans, also protects
the body from UV and other hazardous radiations that can damage skin cells. When eumelanin
has been crystalized, it forms both a geometric and a chemical disorder at the same time. It
turns out that both kinds of disorders, may play a complementary role in producing eumela‐
nin’s broadband absorption. The tiny crystals of eumelanin have a chemically ordered state
with intrinsic randomness: the orientations of the stacked molecules are arbitrary and the sizes
of the crystals are different. That combination of order and disorder contributes to eumelanin’s
broadband absorption (12). Recently, it was reported that eumelanin is a naturally existing
nanocomposite that has very critical macroscopic properties as a result of its nanostructure
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properties. All eumelanin molecules share very similar chemistry, although there are more
than 100 variations. It has been proposed that the small variations from one molecule to another
may contribute to the disorder that broadens the ability to absorb UV light (13).
Additionally, different alleles for melanocortin 1 receptor (MC1R) gene have been identified.
The subtypes related to loss of function reduce the production of cAMP after stimulation of
α-MSH, and thus increase the expression of pheomelanin. This is observed in individuals of
light skin, increasing the risk of developing melanoma by the formation of free radicals after
UV ray exposure.
Recently, a study was performed in 789 patients with diagnosis of melanoma. In order to
characterize these patients according to their levels of sun exposure, three groups were
established in the study: intermittent, chronic, and absence of exposure [14]. The vast majority
of patients were in the first group. These melanomas were present in skin locations exposed
to sun radiation in an intermittent manner. SSM and NM belong to this group. Multiple
common and atypical nevi may constitute a marker of risk of these melanomas. The second
group was formed by patients with melanomas in skin areas with chronic sun exposure,
showing all the damage and premise typical of this location. LMM belongs to this group.
Finally, the third group corresponds to melanomas present in skin areas with no sun exposure,
usually diagnosed in late stages. This group includes ALM and mucosa melanoma, which
usually are thicker at diagnosis and have worse prognosis [15, 16, 17]
4. Acral lentiginous melanoma
Acral lentiginous melanoma (ALM) distinguishes itself from the other subtypes for many
characteristics, mainly histological and clinical-prognostic. A huge controversy regarding the
cause of its worse prognosis, has been going on since its description.
ALM usually occurs on palmoplantar or subungual areas (Fig 2), lacking hair. Similar to NM,
it is very aggressive when its proliferative vertical phase develops. It is more commonly found
in individuals with dark skin (35-60%), oriental population and Afro-Caribbean. Considering
its localization, it is thought to be UV-protected by the thickened stratum corneum and the
nail matrix. ALM is rare in Caucasian populations (1-5%), but has a higher incidence among
our population and Latin-Americans with dark skin(8, 9, 18). However, for individuals with
lighter skin in our population, SSM is the most frequent.
According to the data of The National Cancer Institute Surveillance, Epidemiology and End
Results, ALM is the least frequent histological subtype in the USA, with a 2-3% frequency.
However, it shows a higher percentage among afroamerican people and Asians.
Reed described for the first time ALM as pigmented lesions of the extremities, mainly of the
plantar and palmar regions, that were characterized by a phase of lentiginous (radial) growth,
which evolved in months or years to the invasive vertical phase.(19)
Arrington was the first to notice that this type of melanoma was more prevalent among the
African American population and that their prognosis was less favorable due to being
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diagnosed at an advanced stage. Yet, it was not documented by the SEER as a different
histological subtype until 1986 [20]. Usually, ALM is not associated with nevi, family history
or gene susceptibility known to melanoma. In its great majority, ALM are diagnosed as thick
melanomas which in most cases are usually presented in their late phase, with a worse
prognosis and a lower survival rate than the most common subtypes of melanoma associated
with chronic sun exposure [20].
Pereda et al, reported the Clinical presentation of ALM in patients from Spain. In seventeen
of them, ALM was found on a foot and in six on a hand. Four ALMs of the hand were
subungueal. Most of the foot ALMs were located on the sole (twelve cases) [22].
Figure 2. A subungueal tumor of a 71-year-old male patient with an advanced ALM (thick Breslow), on the thumb of
the left hand. ALM is the most prevalent subtype in Mexicans and LatinAmericans. It is usually found on hands and
feet: palms and soles, wrists and heels, and under the nails. ALM and NM are usually diagnosed in later stages, unlike
SSM and LMM. The most affected sites are by far the feet and nails. Initially, they may be misdiagnosed as a mole, an
ulcer, an abscess, a wart, a nail bed dystrophy or as the result of a trauma.
The most frequent location of ALM is in the feet (Figure 1), mainly the plantar region and the
first finger, as in subungual areas in the majority of non caucasians racial groups. This has led
to the conclusion that trauma may be an important factor of ALM, and not sun exposure [22].
Even when the superficial region of the palms and plantar region are similar, in the plantar
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region there is a continuous exposure to pressure, friction, maceration and irritation. Never‐
theless, there are counterarguments towards this theory, including that the hands are more
exposed to UV radiation and acute trauma. In addition, it has not been possible to prove
changes in the incidence of plantar melanoma when some African tribes began urbanization
and the use of shoes.
Another important factor in the predominance of plantar ALM, is the fact that there is a
50%  greater  amount  of  melanocytes  there  than  in  the  palms  [23,  24].  The  research  of
Ghadially proposed that trauma during less than 12 months, did not increase the risk of
melanoma in the Xiphophorus fish model [25]. Troyanova [26] described mechanical trauma
on previous pigmented skin lesions as a risk factor for the formation of  melanoma and
remarks  that  trauma  has  to  be  carefully  checked.  Recently,  an  amelanotic  subungueal
melanoma arising  after  trauma was  reported  by  Rangwala  [27].  Melanomas  formed on
burns  scars  and tattoos  have  also  been frequently  publishedin  recent  years.Of  687  Chi‐
nese  melanoma  patients,  15.2%  showed  a  strong  association  between  trauma  in  the
extremities and melanoma [28].
Clinical experience coming from medical attention given to patients of melanoma treated in
two of the major oncological centers of our nation, shows that AM occurs in no photo exposed
areas [5], mainly in lower extremities (more than 80% of the cases) and in subungual regions
(Figure 3). This information has been reported by the Mixed Tumor Unit from the Oncologic
Service (General Hospital of Mexico) and the Dermatologic Center ”Ladislao de La Pascua”,
Mexico City [18]
Figure 3. ALM on the foot of a 61-year-old male patient, with indolent growth. The Oncology Unit of the General Hos‐
pital of Mexico reports that more than 50% of ALMs are presented on the lower extremities (mainly on the soles and
subungueal areas. Being the toe by far, the most affected).
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Figure 4. A subungueal tumor of a 54-year-old male patient with an advanced amelanic melanoma. ALMs are usually
diagnosed in the later stages unlike SSM and LMM. It was misdiagnosed as a bleeding ulcer of progressive growth.
Figure 5. A plantar tumor of a 65-year-old male patient. The lower extremity is the most common anatomic location
reported for mexicans. Initially this case was diagnosed as a pigmented lesion of a fast vertical phase progression.
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5. Molecular alterations in melanoma
Melanoma arises through a complex process of cellular mutations and a loss of keratinocyte
control over growth and differentiation. As malignant melanoma progresses, it develops
through interaction between dysfunctional melanocytes and the tumor microenvironment.
This in turn, allows the formation of nevocyte nests at the demal-epidermal junction and is
accompanied with changes in both, keratinocytes and local adhesion molecules (29). The
progression from healthy melanocyte to melanoma occurs through mutations within the
tumor and through alterations of the cellular environment.
In the skin, tissue homeostasis is critical in cellular regulation and melanoma breaks this
regulation through multiple processes. Defining intercellular molecular dialogues in human
skin  promises  to  provide  key  information  about  the  transformation  of  melanocyte  to
melanoma. A great number of genes and proteins have been reported to play an essential
role in this transformation. The most important are: B-RAF, c-KIT, PTEN, p16, p53, cyclin1,
ARF, K-RAS (30).
6. Familial melanoma
It has been reported by a meta-analysis that the presence of at least one-first degree relative
with melanoma increases to double or more, the risk of developing this disease.
Many genetic studies in melanoma-prone families lead to the identification of CDKN2A as
the main familial  melanoma gene.  This  gene is  located at  the chromosome 9p21 region.
CDKN2A  encodes  two different  proteins:  INK4A (p16)  and ARF (p14).  In  order  to  pro‐
duce  these  two  proteins,  the  use  of  alternative  promoters  and  different  first  exons  is
necessary.  Exon  1α  is  used  for  INK4A  and  1β  for  ARF.  The  second  exons  of  the  two
transcripts  are  translated  in  distinct  reading  frames,  encoding  two  completely  different
proteins (with no amino acid homology). Nevertheless, both proteins share potent anticanc‐
er activities. INK4A inhibits the G1 cyclin-dependent kinases (CDKs) 4/6, which phosphor‐
ylate and inactivates the retinoblastoma protein (RB). After that, the S-phase is allowed to
occur.  Loss  of  INK4A function promotes  RB inactivation resulting in cell  cycle  progres‐
sion.  ARF  (Alternative  Reading  Frame)  inhibits  MDM2  mediated  ubiquitination  and
degradation of p53. Loss of ARF, inactivates p53. Alterations of p16 are associated to familial
melanoma in 20% and in 40% to sporadic melanoma [31].
7. Melanomas with intermitent sun exposure
As it was mentioned earlier, more than 90% of melanomas are diagnosed in white and light
skinned populations. The majority of the international studies have addressed these popula‐
tions, since they are at higher risk of developing melanoma. Thus, most reports are drawn from
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data of white and light skinned populations. The main alterations reported in SSM and NM,
are B-RAF and N-RAS mutations.
7.1. BRAF
It is a tyrosine and threonine kinase that participates in the signal transduction known as Ras/
Raf/MEK/ERK/MAP kinase. BRAF functions to regulate the MAPK/ERK pathway, which is
conserved in all eukaryotes. This pathway acts as a signal transducer between the extracellular
environment and the nucleus, activating downstream transcription factors to induce a range
of biochemical processes including growth and differentiation, proliferation and migration
associated to the ability of tissue invading [32, 33, 34]. Through direct secuentiation of PCR
products, three substitutions of simple bases have been demonstrated. The most prevalent
(95% of the cases) is constituted by the transversion of T1799A, occurring on exon 15 of
BRAF, and causes the substitution of the amino acid valine for glutamic acid in position 599
(V599E). Such position has recently been modified to V600E.
Other BRAF mutations that cause carcinogenesis exist, such as K601E or those affecting exon
11, but they rarely occur in melanoma. A fusion of BRAF to AKAP9, by a paracentromeric
inversion of the long arm of chromosome 7 has been observed in cases associated to ionized
radiation exposure. This produces an oncogene, AKAP9-BRAF, which also results in a
constitutive activation of the MAP kinase pathway [35, 36, 37].
Exon 15 BRAF mutations in melanoma were first reported in 2002. The number of reports of
BRAF mutations in primary melanoma tissue increases continually. Varying prevalences in
primary melanoma tissue have been detected, from 41% to 88% in SSM. These BRAF alterations
alone, are not capable of demonstrating neither the immortalization of malignant cells, nor the
progression of the disease further more than a nevus [37].
A pilot BRAF mutation study in ALM patients was carried out by collaboration between the
Genetic Service of the General Hospital of Mexico and the Molecular Oncology Laboratory of
the School of Medicine at the National Polytechnic Institute. DNA sequencing of seven ALM
samples of Mexican patients (General Hospital of Mexico) showed no T1799A mutation in any
of the studied samples (M. Sc. Thesis, 2012) [38].
7.2. NRAS
RAS are among the most frequently mutated oncogenes in human cancers. They show different
mutation patterns and spectrums in all members: NRAS, HRAS and KRAS. The isoforms share
a high degree of similarity, although each one displays preferential coupling to particular
cancer types.
RAS play a fundamental role in the signaling pathway of MAP kinase. Extracellular signals
such as hormones, cytokines, and various growth factors interact with their receptors to
activate the small G-proteins of the RAS family. This pathway includes BRAF and it contributes
to the control of cellular proliferation, particularly malignant cell proliferation. RAS also
controls apoptosis through the PI3K-PTEN-Akt pathway.
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SSM  shows  mutations  almost  exclusively  in  NRAS.  A  prevalence  of  5%  to  10%  NRAS
mutation has been reported. However for hereditary melanomas, the prevalence increases
to 80%. Most cases of  NRAS  mutation are in codon 61.  NRAF  and BRAF  mutations are
mutually exclusive [39].
8. Melanoma with chronic sun exposure
There  are  similarities  between this  type  of  melanoma and those  without  sun exposure.
However,  there  are  differences  with  ALM  since  they  show  much  lower  mutational
characteristics.
KIT (CD117) encodes a tyrosine kinase receptor for stem cells factor and plays a key role in
melanocyte development, migration and proliferation. KIT is found on chromosome 4 and
may be altered in a variety of different types of cancers. It is mutated in 28% of LMM, 36% in
ALM, and is absent in melanomas with intermittent sun exposure. KIT over expression during
the vertical growth phase of melanoma development supports the hypothesis of its participa‐
tion in late stages of the disease. It is the target of several small molecules inhibitors such as
imatinib, being a therapeutic target for this type of melanoma. Different roles of KIT among
different types of melanoma, give additional evidence that each subtype can be considered
different biologically and genetically [40].
9. Melanoma without sun exposure
ALM and mucosal melanomas have an inverse correlation among mutations of BRAF and
NRAS. The increase in the copy number of Cyclin D1, CDK4, KIT and ABCB5 has also been
reported.
9.1. CYCLIN D1
It is an important regulator of transition of the cell cycle for phases G1/S. It also participates in
the phosphorylation of RB protein by binding kinase 4, cyclin dependent. Many studies have
revealed a highly organized sequence of events indispensable for promotion of continued
proliferation. The decision to continue cell cycle progression occurs when cellular RAS induces
the elevation of cyclin D1. These levels are maintained through G1 phase and are necessary
for the initiation of S phase, thus resulting in immediately reduced cyclin D1 levels. One
requirement for DNA synthesis, is the reduction of cyclin D1 to low levels during the S phase.
This forces the cell when it enters G2 phase, to induce high cyclin D1 levels once more. Thus,
cyclin D1 is proposed to be a switch activator in the regulation of continued cell cycle pro‐
gression [41, 42].
Cyclin D1 frequent amplification was reported in 44.4% of ALM by Sauter et al, Cyclin D1 was
overexpressed in all cases with amplifications and in 20% of cases without amplification.
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Cyclin D1 may be an oncogene in melanoma and that targeting its expression can be thera‐
peutically useful in the future for ALM [42].
9.2. CDK4
It is a union protein of cyclin D1, found in chromosome 12q14. During early stages of phase
G1 of the cell cycle, Cyclin D binds to kinase dependent cyclin 4 or 6 (CDK4 or CDK6) and the
resulting complex “frees the brake” that limits the progression towards late G1, going into
phase S. The cyclin D-CDK4/6 complex releases a potent inhibitor of the cell cycle progression:
the one formed by protein pRB and inactive transcription factors. The types of melanoma
having an increase in the number of copies of CyclinD1 and CDK4 have less possibilities of
responding to the therapeutic target used in BRAF, such as Vemurafenib.
9.3. ABCB5
Human ATP-binding cassette transporter, also known as P-glycoprotein, is related to the
subfamily  of  multidrug  resistant  genes  (MDR).  The  ABCB  subfamily  includes  eleven
members that have different expression patterns. Whereas the functions of several transport‐
ers of the ABCB family are not known, there is some information about ABCB5 in relation
to its pattern of expression or its associated function [43]. It has been described by Frank
et al [44, 45] described it and it was implicated in the regulation of progenitor cell fusion
(located in chromosome 7p21-15). Their study used an enriched culture of human epider‐
mal melanocytes isolated from the foreskins of healthy donors and melanoma cell  lines.
They showed a higher and more intense ABCB5 expression in ALM than in SSM. Herrera-
Gonzalez and her team [46], reported a 90% overexpression of ABCB5 in ALM samples of
Mexican patients by using RT-PCR. A direct relationship between mRNA expression and
the aggressiveness of ALM was also shown.
10. Conclusion
In regard to the progression of human cancer, it is universally thought, that it develops from
a single mutated cell, followed by malignant clonal expansion secondary to additional genomic
and genetic alterations. As the malignant cells continue to acquire these alterations, tumor sub-
clones with distinct phenotypic advantages (47) for its progression may be produced: for
example invasion, proliferation, ability to colonize different organs, etc. In many cancers,
regulation of specific signaling molecules also goes awry, affecting a host of other proteins and
cellular processes.
In recent years, the histological and phenotypic characteristics of ALM combined with its high
proportion among melanomas in Afro-Americans, Asian and Latin Americans, has confirmed
the thought that this histological type of melanoma may differ biological and molecularly from
its most common counterparts, recognized by its sun exposure and its greater frequency
among Caucasians. While ALM is characterized by a high frequency of focal amplifications
(mainly involving CCND1, CDK4) and deletions, the most common cutaneous melanomas
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exhibit few changes in the number of genetic copies. In a similar way, while BRAF and NRAS
are mutated in 50% and 20% of the cases respectively, mutation in KIT (which codifies the
tyrosine kinase receptor) seems to be absent in the most common cutaneous melanoma.
However, BRAF mutations in ALM constitute approximately 16% of the cases reported by
Curtin et al. [40, 41]
A systematic sequencing was used for the human genome sequence. New technologies allow
sequencing of randomly generated DNA fragments from cancer genomes and thus detect
alterations and copy number variation as well as base substitutions, to identify most somatic
mutations in an individual cancer genome. Pleasance et al, sequenced the complete genome
of the COLO-829 cell line, an immortal and cancer derived from a metastasis of a melanoma
from a 43 year-old-male. In their study they identified 33,345 somatic base substitutions [48, 49]
The study of Turajlic et al. [50] is the first to characterize the mutational spectra in ALM. They
used a whole genome sequencing to characterize punctual somatic mutations and structural
variation in a primary acral melanoma and its lymph node metastasis. Evidence of transcrip‐
tion-coupled repair was suggested by the lower mutational rate in the transcribed regions and
expressed genes. Primary melanoma and metastasis, at the level of global gene copy number
alterations, loss of heterozygosity and single expressed genes are very similar[50].
These results may be controversial since their sequenced results were on the genome of only
one patient. They cite that despite the perception that acral skin is sun protected, the dominant
mutational signature reveals sun damage. We judge that there is no solid data regarding the
presence of solar exposure on sites where ALM is developed.
Studies  suggest  that  ungual  matrix  does  not  provide  a  complete  protection  against  UV
radiation and it has previously been suggested that UVB can penetrate the human nail [51].
There  are  substantial  variations  in  the  number  and  pattern  of  mutations  in  individual
cancers reflecting different exposures, DNA repair defects and cellular origins [52, 53]. It is
also possible that characteristics of different mutations are induced by the inefficiency of
pyrimidine dimers repaired by excision of nucleotide due to the presence of a mutation in
ERCC5 [54, 55].
Several studies support the hypothesis that ALM is a different genetic subtype and its inherent
heterogeneity represents a challenge in the era of directed therapy [56].
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